Outcomes of Patients with Bacillus Calmette-Guerin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer as Defined by the U.S. Food and Drug Administration.

ABSTRACT:

Background

Limited data are available on the outcomes of patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to intravesical bacillus Calmette-Guérin (BCG), as defined by the United States Food and Drug Administration.

Objective

To define the outcomes of patients with BCG-unresponsive NMIBC.

Methods

This was a retrospective, single-institution observational cohort study. Records of patients managed at our institution for BCG-unresponsive NMIBC between 2005 and 2020 were reviewed and clinical outcomes evaluated.

Results

The study included 149 patients. Management was with initial radical cystectomy in 60 patients (40%) and initial bladder-sparing therapy (BST) in 89 patients (60%). Overall survival was greater among patients undergoing RC than

SUBMITTER: Howard JM 

PROVIDER: S-EPMC11181681 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature